Paper Details

  1. Home
  2. Paper Details

Safety and immunogenicity of sequential administration of PCV13 followed by PPSV23 in pneumococcal vaccine-naïve adults aged ≥ 65 years: Comparison of booster effects based on intervals of 0.5 and 1.0 year.

Author: AkedaYukihiro, AzumaMomoyo, HanibuchiMasaki, MorinoSaeko, MotokiYumi, NishiokaYasuhiko, OishiKazunori

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This open-label study compared the safety and immunogenicity of sequential administration of 13-valent pneumococcal conjugate vaccine (PCV13) followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23) at intervals of 0.5 years and 1 year in adults aged ≥ 65 years.
Paper Details　
Original Abstract of the Article :
An open-label study was conducted to compare the safety and immunogenicity of a sequential administration of 13-valent pneumococcal conjugate vaccine (PCV13) followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23) between an interval of 0.5 (0.5-y) and 1 year (1.0-y) in adults aged ≥ 65 y...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.vaccine.2022.12.060

データ提供：米国国立医学図書館（NLM）

Pneumococcal Vaccination: A Strategy for Protecting Our Elders

Pneumococcal disease is a serious bacterial infection that can cause pneumonia, meningitis, and other complications. This research focuses on the effectiveness and safety of sequential administration of two pneumococcal vaccines – PCV13 and PPSV23 – in adults aged 65 and older. The researchers conducted an open-label study to compare the immunogenicity and safety of these vaccines when administered sequentially with different time intervals.

A Strategic Approach to Pneumococcal Vaccination

This research highlights the potential benefits of sequential pneumococcal vaccination for older adults. By combining these two vaccines, we can potentially enhance immune protection against a broader range of pneumococcal strains.

Optimal Vaccination Strategies for Older Adults

This research provides valuable information for developing optimal pneumococcal vaccination strategies for older adults. By understanding the timing and effectiveness of these vaccines, healthcare providers can tailor vaccination schedules to maximize protection against pneumococcal disease.

Dr.Camel's Conclusion

This research underscores the importance of pneumococcal vaccination for older adults. By understanding the optimal timing and strategies for administering these vaccines, we can help protect our elderly population from this potentially serious disease.

Date :
  1. Date Completed 2023-02-06
  2. Date Revised 2023-02-06
Further Info :

Pubmed ID

36593171

DOI: Digital Object Identifier

10.1016/j.vaccine.2022.12.060

Related Literature

Article Analysis
・Effects of pneumococcal polysaccharide vaccine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.